Unlike SGLT2is—firmly established as a GDMT cornerstone across the EF spectrum—GLP-1 RAs are not yet guideline-recommended, though emerging data suggest potential in patients with obesity, T2DM, or preserved LVEF. This evidence concerns the gene GLP1R and obesity disorder.